Approaches to vancomycin-resistant enterococci

被引:42
作者
Torres-Viera, C
Dembry, LM
机构
[1] Yale New Haven Med Ctr, Qual Improvement Support Serv, New Haven, CT 06504 USA
[2] Yale Univ, Sch Med, Dept Med, Infect Dis Sect, New Haven, CT 06510 USA
关键词
Enterococcus; glycopeptides; glycycline; linezolid; quinupristin-dalfopristin; ramoplanin; treatment; vancomycin-resistant;
D O I
10.1097/00001432-200412000-00006
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose of review This article reviews recent publications regarding new antimicrobial drugs for the treatment of vancomycin-resistant enterococci. Recent findings Newer drugs against vancomycin-resistant enterococci are now available or will soon be available. Quinupristin-dalfopristin, a streptogramin, and linezolid, an oxazolidinone, are effective and safe but only bacteriostatic against enterococi. Bacterial isolates resistant to either antibiotic have been described. Daptomycin, a lipopeptide antimicrobial, has good in-vitro bactericidal activity against enterococci, but very limited clinical data exist regarding the treatment of serious enterococcal infection with this compound. Ramoplanin, the first glycolipodepsipeptide antimicrobial in clinical trials, is not systemically absorbed after oral administration, and is being evaluated for the prevention of bloodstream infection in patients colonized with vancomycin-resistant enterococci. Oritavancin and dalbavancin (both glycopeptides) and tigecycline (a monocycline derivative) are being evaluated in phase II and III trials and are not yet commercially available. Summary Treatment of vancomycin-resistant enterococci continues to be problematical although these new drugs offer some hope. The rational use of antibiotics, strict guidelines for the use of new compounds, and adherence to infection control practices continue to be essential components of the management of vancomycin-resistant enterococci colonization and infection.
引用
收藏
页码:541 / 547
页数:7
相关论文
共 99 条
[1]   In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model [J].
Allen, GP ;
Cha, R ;
Rybak, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2606-2612
[2]  
[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P902
[3]  
[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P565
[4]   Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci [J].
Arthur, M ;
Depardieu, F ;
Reynolds, P ;
Courvalin, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (08) :1875-1880
[5]   Selection of glycopeptide-resistant mutants of VanB-type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis [J].
Aslangul, E ;
Baptista, M ;
Fantin, B ;
Depardieu, F ;
Arthur, M ;
Courvalin, P ;
Carbon, C .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (03) :598-605
[6]   Molecular characterization of vancomycin-resistant enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin [J].
Baden, LR ;
Critchley, IA ;
Sahm, DF ;
So, W ;
Gedde, M ;
Porter, S ;
Moellering, RC ;
Eliopoulos, G .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (04) :1160-1163
[7]   Specificity of induction of glycopeptide resistance genes in Enterococcus faecalis [J].
Baptista, M ;
Depardieu, F ;
Courvalin, P ;
Arthur, M .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (10) :2291-2295
[8]   Emergence of linezolid-resistant Enterococcus faecium during treatment of enterococcal infections [J].
Bassetti, M ;
Farrel, PA ;
Callan, DA ;
Topal, JE ;
Dembry, LM .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 21 (06) :593-594
[9]   First report of a linezolid-resistant vancomycin-resistant Enterococcus faecium strain in Greece [J].
Bersos, Z ;
Maniati, M ;
Kontos, F ;
Petinaki, E ;
Maniatis, AN .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (04) :685-686
[10]   Treatment of vancomycin-resistant Enterococcus with quinupristin/dalfopristin and high-dose ampicillin [J].
Bethea, JA ;
Walko, CM ;
Targos, PA .
ANNALS OF PHARMACOTHERAPY, 2004, 38 (06) :989-991